ImaginAb

Focus: ImaginAb is a biotechnology company specializing in imaging products and antibody therapeutics, founded in 1985 and headquartered in Inglewood, CA. The company focuses on oncology and infectious disease applications with a pipeline of diagnostic imaging agents and therapeutic antibodies.

Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About ImaginAb

AI assessmentNot Hiring

No open roles listed right now. Follow ImaginAb to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

[89Zr]Df-IAB22M2C PET/CT scan

Lymphopenia Due to COVID-19

N/A

Clinical Trials (1)

NCT04874818CD8+ T-cell PET/CT Imaging in COVID-19 Patients

N/A

Help build intelligence for ImaginAb

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized focus on antibody engineering and molecular imaging—a differentiated technology platform in oncology diagnostics
Diversified pipeline across multiple cancer types (melanoma, prostate, NSCLC, bladder) reduces single-asset dependency risk
39-year operational history demonstrates organizational persistence in a challenging biotech landscape

Watch Out For

Currently zero active job openings suggests limited hiring and potential organizational constraints
No marketed products in dossier indicates pre-commercial or development-stage company with execution risk and limited revenue stability
Early-stage pipeline (4 Phase 1, 6 Phase 2, 0 Phase 3) means minimal near-term regulatory catalysts and longer time to valuation events

Generated by Claude from ImaginAb's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Bempegaldesleukin

Metastatic Melanoma

Phase 1

[124I] PSCA-Minibody PET/CT imaging of the whole body

Prostate Cancer

Phase 1

Clinical Trials (1)

NCT02092948Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Phase 1

Zirconium Zr 89 Crefmirlimab Berdoxa

Melanoma (Skin)

Phase 1